Milestone Pharmaceuticals (MIST) Common Equity (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Common Equity came in at $36.0 million in Q1 2026, up 688.75% YoY from $4.6 million in Q1 2025, and down 13.69% on a QoQ basis from $41.8 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Common Equity (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Common Equity data on file, last reported at $36.0 million in Q1 2026.
- Quarterly Common Equity rose 688.75% year-over-year to $36.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.0 million (up 688.75% YoY) and the FY2025 annual result came in at $41.8 million, up 217.71% from the prior year.
- Common Equity slipped to $36.0 million in Q1 2026, from $41.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $100.8 million in Q1 2022 to a low of -$17.7 million in Q2 2025.
- A 5-year average of $38.5 million and a median of $36.0 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity slumped 155.49% — and 2026, when it surged 688.75%.
- Tracing MIST's Common Equity over 5 years: stood at $66.3 million in 2022, then plunged by 74.72% to $16.8 million in 2023, then declined by 21.61% to $13.1 million in 2024, then jumped by 217.71% to $41.8 million in 2025, then decreased by 13.69% to $36.0 million in 2026.
- The last three Common Equity figures came in at $36.0 million (Q1 2026), $41.8 million (Q4 2025), and $20.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - | 18.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.22 Mn |
| Mar 31, 2026 | 36.05 Mn |
| Dec 31, 2025 | 41.77 Mn |
| Sep 30, 2025 | 20.50 Mn |
| Jun 30, 2025 | -17.75 Mn |
| Mar 31, 2025 | -6.12 Mn |
| Dec 31, 2024 | 13.15 Mn |
| Sep 30, 2024 | 24.01 Mn |
| Jun 30, 2024 | 31.98 Mn |
| Mar 31, 2024 | 39.92 Mn |
| Dec 31, 2023 | 16.77 Mn |
| Sep 30, 2023 | 28.50 Mn |
| Jun 30, 2023 | 40.41 Mn |
| Mar 31, 2023 | 53.94 Mn |
| Dec 31, 2022 | 66.35 Mn |
| Sep 30, 2022 | 77.16 Mn |
| Jun 30, 2022 | 86.66 Mn |
| Mar 31, 2022 | 100.76 Mn |
| Dec 31, 2021 | 112.60 Mn |
| Sep 30, 2021 | 127.42 Mn |